

CRYOCOR INC  
Form 8-K  
August 03, 2007

---

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

---

**Form 8-K**

---

**Current Report Pursuant to Section 13 or 15(d) of  
The Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): August 2, 2007**

---

**CryoCor, Inc.**

(Exact name of registrant as specified in its charter)

---

**Delaware**  
(State or other jurisdiction

of incorporation)

**000-51410**  
(Commission File Number)

**33-0922667**  
(I.R.S. Employer

Identification No.)

**9717 Pacific Heights Boulevard**

**San Diego, California**  
(Address of principal executive offices)

**92121**  
(Zip Code)

**Registrant's telephone number, including area code: (858) 909-2200**

**Not Applicable.**

(Former name or former address, if changed since last report.)

---

## Edgar Filing: CRYOCOR INC - Form 8-K

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  
  - .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  
  - .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  
  - .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**Item 8.01 Other Events.**

On August 2, 2007, we issued a press release announcing that the U.S. Food and Drug Administration has granted pre-market approval to our Cardiac Cryoablation System for the treatment of right atrial flutter. The text of this press release is attached as Exhibit 99.1 and is incorporated herein by reference.

**Item 9.01 Financial Statements and Exhibits.**

**(d) Exhibits.**

99.1 Press release of CryoCor, Inc. dated August 2, 2007.

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**CryoCor, Inc.**

By: /s/ Gregory J. Tibbitts  
Vice President, Finance and Chief Financial Officer  
*(Principal Financial and Accounting Officer)*

Date: August 2, 2007

**INDEX TO EXHIBITS**

99.1 Press release of CryoCor, Inc. dated August 2, 2007.